Capitalmind
Capitalmind
Actionable insights on equities, fixed-income, macros and personal finance Start 14-Days Free Trial
Actionable investing insights Get Free Trial

10 ArticlesSTAR

1 / 1

Strides and Sequent Scientific Demerger into Solara : What is in it?

When we buy a tablet (drug) , the money we are paying is for the active pharmaceutical ingredients also called API which is the key ingredient in a drug that ...

Apr 24, 2018

solara-strides-demerger.png

Earnings Report Closing Piece : 3QFY17 : 663 Companies Till Date With Management Comments!

Here is a quick summary of the 3QFY17 financial results for all the companies announced till date. This is the final results piece for 3QFY17 having covered ...

Feb 23, 2017

3QFY17-Communication-Services-23022017.png

Earnings Report: 3QFY17 : 495 Companies Till Now With Management Comments

Here is a quick summary of the third quarter financial results for all the companies announced till date. For some companies, management comments have been ...

Feb 11, 2017

Sectoral-10022017.png

Strides Acquires Perrigo’s US FDA Approved API Facility In India

Strides Shasun has announced the signing of definitive agreements to acquire the entire shareholding in Perrigo API India for Rs. 1,000 million (Rs. 100 crore) ...

Dec 09, 2016

Strides-Shashun-Share-Price-9-December.png

Strides Acquires PediaCare®From Moberg Pharma For US $5 Million

Strides Shashun is set to acquire the brand PediaCare from Moberg Pharma for a total consideration of $5 million along with the current inventory. PediaCare ...

Nov 25, 2016

Strides-Share-Price-25-November-2016.png

Strides Gets a $30m Escrow Payout After Settling with Mylan for $70m for Regulatory Issues

In the latest filing with the exchange, Strides Shasun has settled with Mylan for about $70 million for Regulatory and General Claims on the $1.75 ...

Nov 03, 2016

Strides-Share-Price-3-November-2016.png

Strides Arcolab Doubles Its Profits, Settles Regulatory Issues With Mylan for $70m

Strides Arcolab – a pharmaceutical company engaged in differentiated pharma generics, branded generics, and bio-pharma products. Driven by Formulations ...

Oct 30, 2016

Earnings-Report-Feature-Image.png

Why is FIPB Rejecting the Request for the Strides-Shasun Merger?

So Strides Arcolab was going to merge with Shasun. This merger was cleared by shareholders. Then it was cleared by the Competition Commission. And ...

Jun 17, 2015

Strides Up 12% on FDA Approval, Portfolio Gains

This is a Capital Mind Premium post, sent on April 26, 2014. Strides Arcolab has seen a surge in its stock price on news that the FDA continues its approvalfor ...

Apr 28, 2014

Premium: Strides Arcolab Declares Rs. 500 Dividend, a 56% Yield – Good Deal?

This is an archive for Capital Mind Premium subscribers, sent on 14th December 2013. The Case of Strides Arcolab Strides Arcolab recently sold it’s Agila ...

Dec 15, 2013

Join Capitalmind Premium

Starts at ₹1,999/mo

Get access to our equity, fixed income, macro and personal finance research, model equity and fixed-income portfolios, exclusive apps, tutorials, and member community.